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Global lung health: the dangers of mild lung function 
impairment
The relationship between low lung function and in­
creased mortality risk, especially in the context of 
ageing and exposure to noxious particles and gases, 
was established several decades ago.1–3 However, it 
was not until recently that low peak lung function 
in early adulthood (and thus the vital lung function 
trajectory that followed, independently of the ageing 
process) was associated with an increased prevalence, 
and about a decade earlier incidence, of respiratory 
and cardiovascular abnormalities, as well as premature 
death.4,5
In The Lancet Global Health, MyLinh Duong and 
colleagues6 provide further evidence supporting a rela­
tionship between impaired lung function and respiratory 
and cardiovascular abnormalities and death, with data 
from the prospective urban rural epidemiology (PURE) 
study—an international study involving 126 359 adults 
from 628 urban and rural communities located in 
high­income, middle­income, and low­income countries, 
thus representing a large and genetically diverse 
population exposed to a wide variety of environmental 
risk factors. Participants (aged 35–70 years at enrolment) 
were followed up for a median period of 7·8 years 
(IQR 5·6–9·5) to record cardiovascular and respiratory 
disease events and deaths. Reduced lung function 
(measured as country­standardised forced expiratory 
volume in 1 s [FEV1] values) was associated with increased 
mortality, incident cardiovascular disease, and respiratory 
hospitalisations. This relationship was present across all 
levels of impairment of FEV1 (hazard ratio for mortality 
1·27 [95% CI 1·18–1·36] for mild, 1·74 [1·60–1·90] for 
moderate, and 2·54 [2·26–2·86] for severe impairment 
vs no impairment). Notably, the population­attributable 
risks for death or cardio vascular disease from mildly to 
moderately impaired FEV1 (0–2 SDs below the population 
mean; clinically normal) were greater than those of 
severe FEV1 impairment (more than 2 SDs below the 
population mean), contributing substantially more than 
tobacco use or previous cardiovascular disease to risk. 
Importantly, this effect was reproduced across different 
country­income levels, rural and urban communities, 
and different intercountry risk exposures,6 which include 
tobacco smoke and solid­fuel cooking. On the basis of 
these observations, Duong and colleagues concluded 
that impaired lung function (in terms of reduced FEV1) 
is a strong, independent, and generalisable predictor 
of mortality, cardiovascular disease, and respiratory 
hospitalisation events.6 These observations raise a 
number of questions.
The first question regards the mechanisms underlying 
the association between reduced lung function and 
adverse health outcomes. As noted in our previously 
published paper,7 there are different lung function 
trajectories through life, and we propose that these 
trajectories are determined by a dynamic and probably 
cumulative set of gene–environment interactions 
acting across the lifespan of an individual, which are 
still poorly defined mechanistically. Within this con­
text, these different trajectories have important health 
consequences, including an earlier prevalence and 
incidence of cardiovascular morbidities and premature 
death;7 therefore, the genetic (or genomic) factors that 
govern the abnormal development of the lung might 
also be associated with the abnormal development or 
malfunction of other systemic organs. Accordingly, 
Horikoshi and colleagues8 reported that the genetic loci 
associated with birthweight were also associated with 
the development of adult cardiovascular and metabolic 
disease.
Further questions, with important health­care 
implications, arise from the finding that much of the 
effect on mortality and cardiovascular disease is from 
FEV1 within the currently accepted normal clinical 
levels. Should we still consider mild impairment of FEV1 
to be within the normal range? Should lung function 
be routinely tested in early adulthood to identify 
individuals who are at increased risk and offer them 
targeted health care; and, if so, how will we be able 
to promote lung health in these apparently healthy 
individuals? Finally, how should these findings be 
translated into practice for public health or clinical 
practice?
We suggest that spirometry—an easy, cheap, and 
reproducible test—should be used much more often 
and earlier in order to identify this group of high­risk 
individuals. In this context, impaired lung function, 
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particularly in early adulthood, should be considered a 
canary in a coal mine, used to raise the alert for potential 
future risks.9
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